Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT125-802 in Advanced Solid Tumors
NCT06403436Phase 1Completed
- Sponsor
- TOLREMO therapeutics
- Start
- Nov 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of TT125-802 in solid tumor, sponsored by TOLREMO therapeutics. Primary endpoints: Frequency and severity of adverse events (AEs) and serious adverse events (SAEs) at 16 weeks, Frequency of dose interruptions and dose reductions at 16 weeks and 2 more. Started Nov 2023; status: completed.
02
Drugs
TT125-802
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06403436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06403436.